Jacobs Levy Equity Management
BIO icon

Jacobs Levy Equity Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Jacobs Levy Equity Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,349
Closed -$808K – 976
2025
Q2 		$808K Hold
3,349
– – ﹤0.01% 796
2025
Q1 		$816K Buy
+3,349
New +$1.01M ﹤0.01% 849
2017
Q2 		– Sell
-1,080
Closed -$215K – 932
2017
Q1 		$215K Buy
+1,080
New +$208K ﹤0.01% 781
2015
Q2 		– Sell
-2,226
Closed -$301K – 802
2015
Q1 		$301K Sell
2,226
-93,216
-98% -$11.6M 0.01% 650
2014
Q4 		$11.5M Buy
95,442
+16,300
+21% +$1.88M 0.2% 154
2014
Q3 		$8.97M Buy
79,142
+7,215
+10% +$855K 0.15% 174
2014
Q2 		$8.61M Sell
71,927
-470
-0.6% -$57.4K 0.14% 195
2014
Q1 		$9.28M Sell
72,397
-25,472
-26% -$3.27M 0.16% 188
2013
Q4 		$12.1M Buy
97,869
+12,640
+15% +$1.54M 0.18% 172
2013
Q3 		$10M Sell
85,229
-3,590
-4% -$423K 0.17% 174
2013
Q2 		$9.96M Buy
+88,819
New +$10.4M 0.18% 165

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Jacobs Levy Equity Management's BIO Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 3,349 shares — an estimated $808K sold.

Jacobs Levy Equity Management first reported a position in BIO in Q2 2013 and held it in 11 quarters. The position peaked at $12.1M in Q4 2013. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,349 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $808K.
  • Jacobs Levy Equity Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 11 quarters.
  • Jacobs Levy Equity Management's Bio-Rad Laboratories Class A position peaked at $12.1M in Q4 2013.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.